Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, acts as a partial agonist at sst 2/sst 5 receptors, exhibiting IC50 values of 0.26 nM and 6.92 nM, respectively. This compound effectively inhibits the release of growth hormone and the production of insulin-like growth factor-1 (IGF-1). Additionally, it either inhibits adenylate cyclase activity or promotes extracellular acidification. Notably, Angiopeptin TFA shows promise for use in coronary atherosclerosis research [1] [2].